Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 20, 2015 4:41pm
139 Views
Post# 23545194

RE:Article about RVX & others in Oncology Discovery Jan 15

RE:Article about RVX & others in Oncology Discovery Jan 15LongRVXer.

Thanks. I scanned this quickly and have saved it to study. To me it is just another reinforcement of how advanced RVX is and it bodes extremely well for Zenith Epigenetics, at least if they are as far ahead in this field as Don claims, and while I've had my doubts and frustrations, I'm beginning to believe it is true and any company that finds themselves in catch up mode will find very attractive but I think that NGN and Eastern had the prescience in this case.

One thing that is good about these companies is that there is not two classes of shares.

It does seem that epigenetics will play a very large role in the future of health care and many diseases including individualized patient treatment.

As I recall RVX started into this about 10 years ago at the direction of Dr Wong and others. No wonder that Eastern (Ken Dart) and NGN are so involved with RVX and Zenith.

Thanks again for the valuable post.
Toinv    :)
Bullboard Posts